Navigation Links
CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response,Against Avian Flu Antigen in Animals

VIENNA, Va., May 23, 2007 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION announces that CEL-1000 increased the immune response against H5 avian influenza antigen in combination with MAS-1, a water-in-oil adjuvant delivery system. These findings were presented on May 23, 2007 by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology at CEL-SCI at the American Society of Microbiologists 107th annual general meeting in Toronto, Canada.

This new finding with CEL-1000 may have broad application for the enhancement of immune responses by individuals who have a poor immune response to vaccinations. It also has application for antigen sparing (reducing the amount/dose of antigen required for protective immunity), and to biodefense and pandemic settings for anti-infectious vaccines.

CEL-1000 has previously been shown to increase the antigenicity of hepatitis B virus (HBV). In challenge studies, CEL-1000 has also previously been shown to protect animals against infection against viruses and unrelated diseases, specifically herpes simplex virus, viral encephalitis and malaria.

CEL-1000 appears to activate innate (very early stage) and Th1 type (cellular) immune responses to induce a broad-spectrum protection against infection in animal models. The innate immune system is generally accepted to be the first line of defense against infectious agents.

CEL-1000, derived from the beta chain of human MHC-II, is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. More information on CEL-1000 is available at www.cel-sci.com.

MAS-1 is a water-in-oil adjuvant delivery system owned by Mercia Pharma.

CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseas es. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter a global Phase III clinical trial for a first line indication in advanced primary head and neck cancer in the U.S. and Canada.

CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460

Web site: http://www.cel-sci.com/

Ticker Symbol: (AMEX:CVM)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. RTA 402 Shown to Protect Animals Against Toxicities of Standard Cancer Treatments
2. Gabapentin Shown Effective for Fibromyalgia Pain
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
5. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
6. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
11. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... NEW YORK , April 27, 2016 /PRNewswire/ ... OASM ), a developer of a new ... today announced positive overall survival results for Paclical/Apealea ... total of 789 patients with epithelial ovarian cancer. ... treatment groups: Paclical/Apealea in combination with carboplatin versus ...
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... April 26, 2016 US demand for ... expand 4.9 percent annually to $27.6 billion in ... facilities to decrease rates of healthcare-associated infections (HAIs) ... equipment, and services.  Although declining, the overall rate ... targeted levels set by the CDC.  Recent statistics ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a network ... on SB 258, the “Rural Health Care Relief” Bill. , The bill, which was ... individuals and corporations which donate directly to a “rural hospital” in Georgia, and goes ...
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart is celebrating its ... location in the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There ... TV. Plus attendees will have the opportunity to meet general dentists Thomas Richards, DDS, ...
(Date:4/29/2016)... New York, NY (PRWEB) , ... April 29, ... ... integrated manufacturer and engineer of patented products, announces the Gyrociser, an exercise invention ... industry is worth $2 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that ... head and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to ... AIRWAY™ is a newly patented safety device secured by nasal surgeons onto the ...
(Date:4/29/2016)... PLAINSBORO, N.J. (PRWEB) , ... April 29, 2016 ... ... consumer digital and print media enterprise focused entirely on patients with cancer, today ... Mirage, California, was chosen as the 2016 CURE® Extraordinary Healer® for Oncology ...
Breaking Medicine News(10 mins):